Cargando…
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures
BACKGROUND: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare hereditary kidney cancer syndrome in which affected individuals are at risk of skin and uterine leiomyomatosis and kidney cancer. HLRCC-associated kidney cancer is a lethal disease with a highly aggressive behavior, and...
Autores principales: | Park, Inkeun, Shim, Young Sup, Go, Heounjeong, Hong, Bum Sik, Lee, Jae Lyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558845/ https://www.ncbi.nlm.nih.gov/pubmed/31182090 http://dx.doi.org/10.1186/s12894-019-0484-2 |
Ejemplares similares
-
Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
por: Choi, Yeonjoo, et al.
Publicado: (2019) -
Hereditary leiomyomatosis and renal cell carcinoma
por: Schmidt, Laura S, et al.
Publicado: (2014) -
Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
por: Seo, Ja Young, et al.
Publicado: (2021) -
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021) -
A Case of Hereditary Leiomyomatosis and Renal Cell Carcinoma
por: Mehrtens, Sarah, et al.
Publicado: (2016)